PMID- 28353568
OWN - NLM
STAT- MEDLINE
DCOM- 20170406
LR  - 20240325
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 13
DP  - 2017 Mar
TI  - Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A 
      meta-analysis of 7 randomized controlled trials.
PG  - e6412
LID - 10.1097/MD.0000000000006412 [doi]
LID - e6412
AB  - BACKGROUND: This study aimed to assess the effectiveness and safety of 
      angiogenesis inhibitors for the treatment of patients with small cell lung cancer 
      (SCLC) via meta-analysis. METHODS: Electronic databases including PubMed, Embase, 
      and Cochrane Library were searched to look for eligible studies through February 
      1, 2016. RCTs comprising angiogenesis inhibitors and nonangiogenesis inhibitors 
      for SCLC patients were investigated. The extracted data including overall 
      survival (OS), progression-free survival (PFS), and objective response rate (ORR) 
      were summarized. In addition, the common adverse events (AEs) were also explored. 
      RESULTS: There were 7 phase II/III RCTs, encompassing 1322 SCLC patients eligible 
      for meta-analysis. In comparison to nonangiogenesis inhibitors, angiogenesis 
      inhibitors treatment was not associated with improvement of PFS [HR = 0.87, 95% 
      CI (0.74-1.02), P = 0.09), OS [HR = 0.99, 95% CI (0.88-1.12), P = 0.91], or ORR 
      [OR = 1.12, 95% CI (0.85-1.47), P = 0.41). Also, there was no improvement in 
      1-year survival rate [OR = 0.96, 95% CI (0.74-1.19), P = 0.63)], 2-year survival 
      rate [OR = 1.00, 95% CI (0.66-1.51), P = 1.00)] or 1-year progression-free 
      survival rates [OR = 0.95, 95% CI (0.69-1.31), P = 0.76)]. However, from subgroup 
      analyses, it was observed that angiogenesis inhibitors improved ORR [HR = 1.66 
      (95% CI 1.02-2.71), P = 0.04] in phase II studies and bevacizumab improved PFS 
      [HR = 0.73 (95% CI 0.42-0.97), P = 0.04]. It is important to note that 
      angiogenesis inhibitors reduced emesis [OR = 0.38, 95% CI (0.17-0.85), P = 0.02], 
      but increased incidence of constipation [OR = 4.02, 95% CI (2.14-7.55), 
      P < 0.0001) and embolism [OR = 2.24, 95% CI (1.45-3.47), P = 0.0003). CONCLUSION: 
      Adding angiogenesis inhibitors to chemotherapy did not improve PFS, OS, ORR, 
      1-year survival rate, 2-year survival rate or 1-year progression-free survival 
      rate for SCLC. However, subgroup analysis revealed that bevacizumab enhanced PFS. 
      Angiogenesis inhibitors also had a high incidence of constipation and embolism.
FAU - Li, Qing
AU  - Li Q
AD  - Department of Medical Oncology, The First Affiliated Hospital of Xi'an JiaoTong 
      University Department of Respiratory Medicine, Xi'an Central Hospital, Xi'an, 
      Shaanxi, P.R. China.
FAU - Wu, Tao
AU  - Wu T
FAU - Jing, Li
AU  - Jing L
FAU - Li, Miao-Jing
AU  - Li MJ
FAU - Tian, Tao
AU  - Tian T
FAU - Ruan, Zhi-Ping
AU  - Ruan ZP
FAU - Liang, Xuan
AU  - Liang X
FAU - Nan, Ke-Jun
AU  - Nan KJ
FAU - Liu, Zhi-Yan
AU  - Liu ZY
FAU - Yao, Yu
AU  - Yao Y
FAU - Guo, Hui
AU  - Guo H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality
MH  - Randomized Controlled Trials as Topic
MH  - Small Cell Lung Carcinoma/*drug therapy/mortality
MH  - Treatment Outcome
PMC - PMC5380252
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2017/03/30 06:00
MHDA- 2017/04/07 06:00
PMCR- 2017/03/31
CRDT- 2017/03/30 06:00
PHST- 2017/03/30 06:00 [entrez]
PHST- 2017/03/30 06:00 [pubmed]
PHST- 2017/04/07 06:00 [medline]
PHST- 2017/03/31 00:00 [pmc-release]
AID - 00005792-201703310-00014 [pii]
AID - MD-D-16-02698 [pii]
AID - 10.1097/MD.0000000000006412 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Mar;96(13):e6412. doi: 10.1097/MD.0000000000006412.